Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy

In adult patients, amifostine appears to ameliorate cisplatin‐related nephrotoxicity and ototoxicity. We assessed the safety and efficacy of amifostine in 11 children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor treated with radiotherapy and vincristine, lomustine, and cispla...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric Blood & Cancer 2004-12, Vol.43 (7), p.780-784
Main Authors: Fisher, Michael J., Lange, Beverly J., Needle, Michael N., Janss, Anna J., Shu, Hui-Kuo G., Adamson, Peter C., Phillips, Peter C.
Format: Article
Language:English
Subjects:
amifostine
Amifostine - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Biological and medical sciences
Child
Child, Preschool
cisplatin
Cisplatin - administration & dosage
Cisplatin - toxicity
Drug Interactions
Ear Diseases - chemically induced
Ear Diseases - prevention & control
Endpoint Determination
Female
General aspects
Humans
Hypotension - chemically induced
Kidney Diseases - chemically induced
Kidney Diseases - prevention & control
Male
Medical sciences
medulloblastoma
Medulloblastoma - complications
Medulloblastoma - drug therapy
Medulloblastoma - radiotherapy
nephrotoxicity
ototoxicity
Protective Agents - administration & dosage
Protective Agents - toxicity
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In adult patients, amifostine appears to ameliorate cisplatin‐related nephrotoxicity and ototoxicity. We assessed the safety and efficacy of amifostine in 11 children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor treated with radiotherapy and vincristine, lomustine, and cisplatin. Amifostine was administered immediately prior to and 4 hr into the cisplatin infusion. Amifostine caused assymptomatic hypotension and hypocalcemia in 18 and 82% of patients, respectively. Despite amifostine use, 78% of patients developed significant ototoxicity. Although relatively well tolerated, amifostine does not appear to have a major impact on ameliorating the risk of developing significant nephro‐ and ototoxicity in children with medulloblastoma. Larger studies will help clarify these findings. Pediatr Blood Cancer 2004;43:780–784. © 2004 Wiley‐Liss, Inc.
ISSN:1545-5009
1545-5017
1096-911X
DOI:10.1002/pbc.20132